New Enterprise Associates

Vori Health offers an integrated medical practice specializing in treating musculoskeletal conditions. Its nationwide, evidence-based approach addresses back, neck, and joint issues through a unique, virtual-first care model. Patients are connected to a collaborative team consisting of a board-certified physician, health coach navigator, and physical therapist for comprehensive care.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Pair Eyewear, Inc. is a New York-based company that specializes in customizable eyeglasses for children. Founded in 2017 by Nathan Kondamuri and Sophia Edelstein, the company offers a unique approach to eyewear by providing base frames and interchangeable top frames that allow kids to express their personal style and interests. By combining functionality with creativity, Pair Eyewear transforms glasses from mere medical devices into a fun and engaging accessory for children. The company's direct-to-consumer model leverages an e-commerce platform, making the purchasing process convenient for parents while enhancing the overall experience for young wearers. Pair Eyewear is committed to offering quality, affordable glasses that are both stylish and practical, featuring hand-polished frames and shatterproof polycarbonate lenses.

Launchpad Therapeutics is an antibody-focused precision oncology company.

Evernow offers comprehensive women's healthcare services focused on menopause. Their platform provides online access to specialized doctors, evidence-based information, treatments, and supportive communities, empowering women to manage hormonal changes and improve their overall health.

Nitra is a financial technology company focused on transforming the healthcare industry through innovative and efficient solutions. It provides a suite of machine learning-powered financial software that includes credit cards, loans, accounts, payments, and expense management tools specifically designed for medical professionals. Nitra's platform enables healthcare providers to streamline their financial operations, allowing them to balance patient care with practice management. Its offerings include a business card that rewards spending and fosters partnerships with various service providers, as well as user-friendly accounting and receipt reconciliation tools. Nitra is committed to equipping the healthcare sector with advanced technology and dedicated support, ensuring that financial management can be both effective and straightforward.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

InCarey is a Shanghai-based company founded in 2011 that specializes in developing a comprehensive medical service platform focused on the management of chronic and vertical diseases. The platform integrates medical, pharmaceutical, and insurance resources to provide a one-stop solution for patients requiring long-term care and support. InCarey's cloud-based online platform facilitates professional disease management services, allowing for direct interaction between doctors and patients. Additionally, it includes an e-commerce component that enables users to conveniently access medications for various chronic conditions. The company is dedicated to enhancing the patient experience through innovative payment services and a holistic approach to chronic disease management.

Pair Eyewear, Inc. is a New York-based company that specializes in customizable eyeglasses for children. Founded in 2017 by Nathan Kondamuri and Sophia Edelstein, the company offers a unique approach to eyewear by providing base frames and interchangeable top frames that allow kids to express their personal style and interests. By combining functionality with creativity, Pair Eyewear transforms glasses from mere medical devices into a fun and engaging accessory for children. The company's direct-to-consumer model leverages an e-commerce platform, making the purchasing process convenient for parents while enhancing the overall experience for young wearers. Pair Eyewear is committed to offering quality, affordable glasses that are both stylish and practical, featuring hand-polished frames and shatterproof polycarbonate lenses.

Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Shape Therapeutics, Inc. is a biotechnology company focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic disorders. Founded in 2018 and headquartered in Seattle, Washington, the company utilizes its proprietary RNAfix technology to edit RNA using the body’s natural cellular machinery. This approach minimizes risks associated with immunogenicity, cellular toxicity, and unintended DNA editing. Shape Therapeutics is dedicated to advancing its innovative platforms for payload, delivery, and manufacturing to enable the development of effective treatments, aiming to address critical health challenges and improve patient outcomes.

Vori Health offers an integrated medical practice specializing in treating musculoskeletal conditions. Its nationwide, evidence-based approach addresses back, neck, and joint issues through a unique, virtual-first care model. Patients are connected to a collaborative team consisting of a board-certified physician, health coach navigator, and physical therapist for comprehensive care.

Spiras Health operates a healthcare service that delivers specialized care to patients' homes for those managing complex chronic conditions. Their multidisciplinary clinical team offers services enhanced by telehealth, digital communications, and remote monitoring, aiming to improve patients' quality of life and reduce unnecessary hospitalizations.

AllyAlign Health, Inc. is a care management company that specializes in supporting patients with chronic and complex medical conditions. Founded in 2013 and headquartered in Glen Allen, Virginia, the company operates an advanced care management platform that facilitates real-time, collaborative care across various healthcare settings. This platform connects patients with care teams and integrates essential health information, care plans, and benefits details, empowering users to make informed care decisions. It offers mobile and web-based access, allowing patients and their families to view, share, create, and update information conveniently from home or from afar. The company's central database is HIPAA compliant and consolidates data from diverse sources, including electronic health records, lab tests, and clinical systems, ensuring comprehensive and meaningful clinical insights through semantic data modeling.

Vori Health offers an integrated medical practice specializing in treating musculoskeletal conditions. Its nationwide, evidence-based approach addresses back, neck, and joint issues through a unique, virtual-first care model. Patients are connected to a collaborative team consisting of a board-certified physician, health coach navigator, and physical therapist for comprehensive care.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Cardionomic is a medical device company developing a catheter-based neuromodulation therapy for acute decompensated heart failure. The device delivers targeted electrical stimulation to cardiac nerves via placement in the right pulmonary artery through the internal jugular vein and modulates autonomic signals to improve ventricular contractility without increasing heart rate. The therapy aims to increase cardiac output, renal blood flow, urine production, and pharmacological tolerance while reducing deleterious hormonal signaling associated with heart failure. It addresses the root cause of ADHF by non-systemically enhancing contractility to improve in-hospital outcomes. The company was founded in 2007 and is based in New Brighton, Minnesota.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

Shape Therapeutics, Inc. is a biotechnology company focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic disorders. Founded in 2018 and headquartered in Seattle, Washington, the company utilizes its proprietary RNAfix technology to edit RNA using the body’s natural cellular machinery. This approach minimizes risks associated with immunogenicity, cellular toxicity, and unintended DNA editing. Shape Therapeutics is dedicated to advancing its innovative platforms for payload, delivery, and manufacturing to enable the development of effective treatments, aiming to address critical health challenges and improve patient outcomes.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

GOQii Inc. is a digital health and wellness company that provides innovative solutions aimed at helping individuals adopt healthier lifestyles. Founded in 2013 and headquartered in Menlo Park, California, with additional offices in Mumbai and Shenzhen, GOQii offers activity tracker wearables and a comprehensive application that monitors various health metrics, including sleep patterns, physical activity, and calories burned. The platform connects users with a diverse range of professional health and fitness coaches, such as nutritionists and personal trainers, who provide personalized guidance through private chats and video calls based on individual health data. Additionally, the app facilitates medical consultations, diagnostic test bookings, and storage of health records in the cloud. GOQii's mission is to empower millions globally to achieve their health goals through a blend of advanced technology and expert support.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

MORE Health, Inc. is a healthcare technology company that has developed a cloud-based physician collaboration platform to facilitate joint diagnosis and treatment planning between attending doctors and specialists. Founded in 2013 and based in Foster City, California, the platform integrates a clinical database containing medical histories, hospital records, lab results, and medical images, along with secure communication tools for real-time discussions. MORE Health offers a variety of services, including a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, it now serves U.S. companies as a supplemental health benefit, providing employees access to top-tier medical expertise during serious health issues. With strategic alliances with prominent medical institutions, MORE Health aims to become a virtual global hospital for serious illnesses, ensuring patients receive the highest quality of diagnosis and treatment when needed.

CareZone is a healthcare platform focused on simplifying personal healthcare management and enhancing coordination among family members and caregivers. The company offers a solution that automates prescription refill reminders, appointment tracking, and provides controlled access to health information, allowing users to manage their healthcare needs efficiently. By centralizing these services in a single interface, CareZone enables individuals to better organize their health management and facilitate communication with those involved in their care.

Goop Inc. is a lifestyle brand that operates an online platform focused on wellness, curated shopping, and lifestyle content. Founded in 2008 by Gwyneth Paltrow, Goop originated as a weekly newsletter but has since evolved into a comprehensive lifestyle site. It offers a carefully curated selection of products, including apparel, beauty items, wellness products, and home goods. The platform also provides valuable content, featuring expert advice on health, fitness, and mental well-being, along with travel recommendations, cooking recipes, and design ideas. Goop aims to serve as a trusted resource for readers, presenting insights and suggestions in a personalized manner rather than through anonymous sources. The brand emphasizes clean beauty and wellness, exemplified by its exclusive skincare line, Goop by Juice Beauty, which aligns with its commitment to quality and holistic living. Based in New York, Goop continues to expand its offerings while maintaining a focus on authenticity and expert-driven content.

MORE Health, Inc. is a healthcare technology company that has developed a cloud-based physician collaboration platform to facilitate joint diagnosis and treatment planning between attending doctors and specialists. Founded in 2013 and based in Foster City, California, the platform integrates a clinical database containing medical histories, hospital records, lab results, and medical images, along with secure communication tools for real-time discussions. MORE Health offers a variety of services, including a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, it now serves U.S. companies as a supplemental health benefit, providing employees access to top-tier medical expertise during serious health issues. With strategic alliances with prominent medical institutions, MORE Health aims to become a virtual global hospital for serious illnesses, ensuring patients receive the highest quality of diagnosis and treatment when needed.

Radiology Partners is a healthcare service company that provides radiology services through a network of onsite centers across multiple states. It delivers diagnostic and interventional radiology to hospitals, health systems, radiology practices, and other facilities, with investments and support designed to help clients grow their practices while preserving autonomy. The company focuses on transforming radiology for radiologists, practices, patients, and families by offering comprehensive imaging services and collaborative partnerships that improve efficiency and care. Radiology Partners is headquartered in Manhattan Beach, California.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Radiology Partners is a healthcare service company that provides radiology services through a network of onsite centers across multiple states. It delivers diagnostic and interventional radiology to hospitals, health systems, radiology practices, and other facilities, with investments and support designed to help clients grow their practices while preserving autonomy. The company focuses on transforming radiology for radiologists, practices, patients, and families by offering comprehensive imaging services and collaborative partnerships that improve efficiency and care. Radiology Partners is headquartered in Manhattan Beach, California.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company based in Morris Plains, New Jersey, that specializes in developing monoclonal antibody-based products for the targeted treatment of cancer. The company is primarily focused on sacituzumab govitecan, an antibody-drug conjugate designed for patients with metastatic triple-negative breast cancer, aiming to position it as a third-line therapy in the United States. Additionally, Immunomedics is engaged in the development of other product candidates, including IMMU-140 for hematologic malignancies and IMMU-130 for colorectal cancer. The company has established clinical collaborations with major pharmaceutical entities to enhance its research and treatment capabilities. Founded in 1982, Immunomedics operates with the goal of delivering innovative therapies to patients with serious diseases. As of October 2020, it functions as a subsidiary of Gilead Sciences, Inc.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Goop Inc. is a lifestyle brand that operates an online platform focused on wellness, curated shopping, and lifestyle content. Founded in 2008 by Gwyneth Paltrow, Goop originated as a weekly newsletter but has since evolved into a comprehensive lifestyle site. It offers a carefully curated selection of products, including apparel, beauty items, wellness products, and home goods. The platform also provides valuable content, featuring expert advice on health, fitness, and mental well-being, along with travel recommendations, cooking recipes, and design ideas. Goop aims to serve as a trusted resource for readers, presenting insights and suggestions in a personalized manner rather than through anonymous sources. The brand emphasizes clean beauty and wellness, exemplified by its exclusive skincare line, Goop by Juice Beauty, which aligns with its commitment to quality and holistic living. Based in New York, Goop continues to expand its offerings while maintaining a focus on authenticity and expert-driven content.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

DOTS Technology Corp, founded in 2013 and located in Natick, Massachusetts, operates a diagnostic platform designed to assist consumers with food allergies. The company is focused on developing a food allergen detection system that allows users to test food on the spot, providing immediate information to enhance decision-making and improve the overall quality of life for individuals affected by food allergies. By advancing point-of-care detection technology, DOTS aims to address the needs of millions of consumers and has applications in both consumer and industrial sectors.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

GOQii Inc. is a digital health and wellness company that provides innovative solutions aimed at helping individuals adopt healthier lifestyles. Founded in 2013 and headquartered in Menlo Park, California, with additional offices in Mumbai and Shenzhen, GOQii offers activity tracker wearables and a comprehensive application that monitors various health metrics, including sleep patterns, physical activity, and calories burned. The platform connects users with a diverse range of professional health and fitness coaches, such as nutritionists and personal trainers, who provide personalized guidance through private chats and video calls based on individual health data. Additionally, the app facilitates medical consultations, diagnostic test bookings, and storage of health records in the cloud. GOQii's mission is to empower millions globally to achieve their health goals through a blend of advanced technology and expert support.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Cardionomic is a medical device company developing a catheter-based neuromodulation therapy for acute decompensated heart failure. The device delivers targeted electrical stimulation to cardiac nerves via placement in the right pulmonary artery through the internal jugular vein and modulates autonomic signals to improve ventricular contractility without increasing heart rate. The therapy aims to increase cardiac output, renal blood flow, urine production, and pharmacological tolerance while reducing deleterious hormonal signaling associated with heart failure. It addresses the root cause of ADHF by non-systemically enhancing contractility to improve in-hospital outcomes. The company was founded in 2007 and is based in New Brighton, Minnesota.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Goop Inc. is a lifestyle brand that operates an online platform focused on wellness, curated shopping, and lifestyle content. Founded in 2008 by Gwyneth Paltrow, Goop originated as a weekly newsletter but has since evolved into a comprehensive lifestyle site. It offers a carefully curated selection of products, including apparel, beauty items, wellness products, and home goods. The platform also provides valuable content, featuring expert advice on health, fitness, and mental well-being, along with travel recommendations, cooking recipes, and design ideas. Goop aims to serve as a trusted resource for readers, presenting insights and suggestions in a personalized manner rather than through anonymous sources. The brand emphasizes clean beauty and wellness, exemplified by its exclusive skincare line, Goop by Juice Beauty, which aligns with its commitment to quality and holistic living. Based in New York, Goop continues to expand its offerings while maintaining a focus on authenticity and expert-driven content.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

ClarVista Medical, Inc. is a California-based company focused on developing innovative products to address challenging ophthalmic conditions. Founded in 2012, it specializes in the HARMONI modular intraocular lens system, which enhances vision optimization during cataract surgery. The company emerged from Prospex Medical, a medical device incubator, and has since developed a robust portfolio of intellectual property. ClarVista Medical has successfully completed the first generation of the HARMONI system and conducted initial human clinical studies. It is currently working on the second generation of the HARMONI system, aiming to conduct larger clinical trials and secure essential regulatory approvals. The company's technology allows for the initial positioning of the lens and facilitates easy exchange of the lens optic, thereby providing healthcare practitioners with a customizable solution for cataract surgery tailored to individual patient needs.

MORE Health, Inc. is a healthcare technology company that has developed a cloud-based physician collaboration platform to facilitate joint diagnosis and treatment planning between attending doctors and specialists. Founded in 2013 and based in Foster City, California, the platform integrates a clinical database containing medical histories, hospital records, lab results, and medical images, along with secure communication tools for real-time discussions. MORE Health offers a variety of services, including a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, it now serves U.S. companies as a supplemental health benefit, providing employees access to top-tier medical expertise during serious health issues. With strategic alliances with prominent medical institutions, MORE Health aims to become a virtual global hospital for serious illnesses, ensuring patients receive the highest quality of diagnosis and treatment when needed.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

U.S. Renal Care operates a nationwide network of outpatient, home, and specialty dialysis centers delivering in-center and at-home hemodialysis and peritoneal dialysis services for end-stage renal disease. The company runs acute dialysis programs in partnership with local hospitals and supports families, caregivers, and physicians in ESRD care. Founded in 2000 and headquartered in Plano, Texas, it develops and operates dialysis centers through collaborations with local nephrologists, serving tens of thousands of patients across multiple states and select territories, including Guam and, according to some sources, Saudi Arabia.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Lumena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for rare liver diseases, particularly cholestatic liver disease. Its lead candidate, LUM001, targets a specific transporter in the intestine, which reduces the risk of systemic toxicities by being minimally absorbed in the body. LUM001 has been extensively studied across 12 clinical trials involving over 1,400 subjects, positioning it for rapid advancement in both pediatric and adult patients. While Lumena's primary objective is to provide novel treatments for rare liver diseases, its therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which are increasingly recognized as significant health concerns in both children and adults.

Pinetree is a Beijing-based company that specializes in providing professional home care services for senior citizens in China. Founded in 2004, Pinetree offers a range of services, including home care, wellness, and insurance, tailored to meet the diverse needs of seniors at various stages of life and with different health conditions. The company's mission is to enhance the physical and mental well-being of elderly individuals, promoting their confidence and ability to live independently while also helping to reduce medical care expenses. Pinetree collaborates with commercial partners to deliver integrated and restorative care, effectively bridging the gap between hospitals, community health centers, and the homes of patients and their families.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Cardioxyl Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease. The company is dedicated to discovering, developing, and commercializing novel technologies in areas where existing treatments are lacking or inadequate. With a strong emphasis on nitroxyl technology, Cardioxyl has established significant expertise in its chemistry, biology, and clinical applications. The company's leading candidate, CXL-1020, is currently undergoing clinical development for Acute Decompensated Heart Failure, a condition that is a primary cause of hospitalization among patients over the age of 65. Through its research and development efforts, Cardioxyl aims to address critical unmet needs in cardiovascular care.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

Bravo Health, Inc. is a managed care organization that specializes in providing Medicare Advantage options, catering specifically to Medicare beneficiaries, including those who are dually eligible for Medicare and Medicaid. The company offers a range of plans, including special needs plans for individuals receiving institutional care or those with chronic health conditions, as well as private fee-for-service plans that allow members to choose their healthcare providers. Additionally, Bravo Health provides Part D prescription drug plans to cover medication needs. The company operates in multiple states, including Delaware, Maryland, Pennsylvania, Texas, and Washington, and has expanded its services to offer prescription drug coverage in 43 states. Founded in 1996 and headquartered in Baltimore, Maryland, Bravo Health was previously known as Elder Health, Inc.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.

CareZone is a healthcare platform focused on simplifying personal healthcare management and enhancing coordination among family members and caregivers. The company offers a solution that automates prescription refill reminders, appointment tracking, and provides controlled access to health information, allowing users to manage their healthcare needs efficiently. By centralizing these services in a single interface, CareZone enables individuals to better organize their health management and facilitate communication with those involved in their care.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

SCI Solutions provides healthcare business process software to a national network of over 550 hospitals, diagnostic imaging centers, physician groups, and post-acute organizations. The company's cloud-based platform enhances healthcare systems through patent-protected, workflow-enabled solutions that streamline patient care across various service areas. With a processing capacity of more than 1.5 billion transactions annually, SCI's Order Facilitator and Schedule Maximizer are recognized as leading referral management and network scheduling platforms in the industry. These offerings have been ranked among the Best in KLAS by KLAS Research. SCI Solutions aims to improve the healthcare system by increasing outpatient volumes, coordinating patient transitions, and enhancing revenue compliance while reducing network leakage. Their platform optimizes patient access, intake, and engagement processes, enabling healthcare enterprises to provide a more consumer-friendly experience. By utilizing advanced rules and workflow engines, SCI Solutions helps healthcare providers proactively manage scheduling and resources, ultimately fostering better physician loyalty, patient satisfaction, and revenue growth.

ClarVista Medical, Inc. is a California-based company focused on developing innovative products to address challenging ophthalmic conditions. Founded in 2012, it specializes in the HARMONI modular intraocular lens system, which enhances vision optimization during cataract surgery. The company emerged from Prospex Medical, a medical device incubator, and has since developed a robust portfolio of intellectual property. ClarVista Medical has successfully completed the first generation of the HARMONI system and conducted initial human clinical studies. It is currently working on the second generation of the HARMONI system, aiming to conduct larger clinical trials and secure essential regulatory approvals. The company's technology allows for the initial positioning of the lens and facilitates easy exchange of the lens optic, thereby providing healthcare practitioners with a customizable solution for cataract surgery tailored to individual patient needs.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

CV Ingenuity, a Palo Alto, CA-based medical device company. CV Ingenuity Corp., a medical device company, develops devices for the treatment of vascular diseases to relieve vascular obstructions, inhibit restenosis, and allow natural vessel healing. It offers Drug Coated Balloon platform for the "Touch-and-Go" treatment of vascular disease. It was incorporated in 2008 and is based in Fremont, California. As of January 10, 2013, CV Ingenuity Corp. operates as a subsidiary of Covidien plc.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Cardioxyl Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease. The company is dedicated to discovering, developing, and commercializing novel technologies in areas where existing treatments are lacking or inadequate. With a strong emphasis on nitroxyl technology, Cardioxyl has established significant expertise in its chemistry, biology, and clinical applications. The company's leading candidate, CXL-1020, is currently undergoing clinical development for Acute Decompensated Heart Failure, a condition that is a primary cause of hospitalization among patients over the age of 65. Through its research and development efforts, Cardioxyl aims to address critical unmet needs in cardiovascular care.

Founded in 2011, Rock Health is a venture capital firm based in San Francisco. It specializes in investing in and supporting startups working at the intersection of healthcare and technology, with a focus on digital health.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

GoodGuide is a comprehensive platform that offers consumers access to the largest and most reliable source of information regarding the health, environmental, and social impacts of various products and companies. It features ratings on over 60,000 products, including personal care items and household cleaners, enabling users to easily identify safe and healthy choices for their homes. By providing expert advice and personalized recommendations, GoodGuide empowers consumers to make informed decisions about the products they purchase. The platform is accessible online and via mobile devices, ensuring that users can obtain the necessary information anytime and anywhere. Additionally, GoodGuide plans to expand its database to include new categories such as toys, electronics, and automobiles, further enhancing its role as a vital resource for consumers seeking safe and environmentally friendly products.

GoodGuide is a comprehensive platform that offers consumers access to the largest and most reliable source of information regarding the health, environmental, and social impacts of various products and companies. It features ratings on over 60,000 products, including personal care items and household cleaners, enabling users to easily identify safe and healthy choices for their homes. By providing expert advice and personalized recommendations, GoodGuide empowers consumers to make informed decisions about the products they purchase. The platform is accessible online and via mobile devices, ensuring that users can obtain the necessary information anytime and anywhere. Additionally, GoodGuide plans to expand its database to include new categories such as toys, electronics, and automobiles, further enhancing its role as a vital resource for consumers seeking safe and environmentally friendly products.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company specializes in balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate sinus anatomy effectively, facilitating the opening of blocked sinus ostia and passageways to promote proper sinus drainage. Acclarent's Balloon Sinuplasty technology and associated Relieva product portfolio provide alternatives to traditional endoscopic surgical methods. The company's devices received FDA clearance and were commercially launched in the United States in 2005, marking a significant advancement in the treatment options available for patients with sinus-related conditions.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company specializes in balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate sinus anatomy effectively, facilitating the opening of blocked sinus ostia and passageways to promote proper sinus drainage. Acclarent's Balloon Sinuplasty technology and associated Relieva product portfolio provide alternatives to traditional endoscopic surgical methods. The company's devices received FDA clearance and were commercially launched in the United States in 2005, marking a significant advancement in the treatment options available for patients with sinus-related conditions.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Cardioxyl Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease. The company is dedicated to discovering, developing, and commercializing novel technologies in areas where existing treatments are lacking or inadequate. With a strong emphasis on nitroxyl technology, Cardioxyl has established significant expertise in its chemistry, biology, and clinical applications. The company's leading candidate, CXL-1020, is currently undergoing clinical development for Acute Decompensated Heart Failure, a condition that is a primary cause of hospitalization among patients over the age of 65. Through its research and development efforts, Cardioxyl aims to address critical unmet needs in cardiovascular care.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company specializes in balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate sinus anatomy effectively, facilitating the opening of blocked sinus ostia and passageways to promote proper sinus drainage. Acclarent's Balloon Sinuplasty technology and associated Relieva product portfolio provide alternatives to traditional endoscopic surgical methods. The company's devices received FDA clearance and were commercially launched in the United States in 2005, marking a significant advancement in the treatment options available for patients with sinus-related conditions.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

ReShape is a company that specializes in providing non-surgical weight-loss solutions and services. Founded in 1998 and based in the United States, ReShape aims to support individuals in achieving their weight-loss goals through innovative approaches. While initially associated with Electronic Design Automation software for the ASIC market, the company has pivoted to focus on health and wellness, offering a range of services designed to aid in weight management without surgical intervention.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.